Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Candidiasis; Aspergillosis

Treatments: Drug: caspofungin acetate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00082524

MK0991-043

Formerly-0404CCAI

2004_100

0991-043

Details and patient eligibility

About

This study is an open label, noncomparative study using an investigational agent for the treatment of documented Candida or Aspergillus infections in pediatric patients (ages 3 months-17 years).

Enrollment: 50 patients

Sex: All

Ages: 3 months to 17 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Children, 3 months through 17 years of age,
• with esophageal candidiasis or
• invasive candidiasis or
• children requiring salvage treatment of invasive aspergillosis.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)